Metabolic surgery can result in type 2 diabetes remission lasting for at least 10 years, and people who relapse still achieve markedly improved glycemic control, shows follow-up from a randomized trial published in The Lancet.
A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.
Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.
The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.
People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.
People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.
Dapagliflozin significantly reduces the risk for worsening heart failure or cardiovascular death in people who have heart failure with preserved ejection fraction, show the results of the DELIVER trial.
Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.